Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| U01DA040213 | U.S. NIH Grant/Contract | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| National Institute on Drug Abuse (NIDA) | NIH |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to test clinical strategies that pediatric providers may use to prevent misuse and diversion of stimulants by their adolescent patients with ADHD.
This study addresses the increase in diversion (selling, sharing, loaning, or trading) of prescription stimulant medications by adolescents with Attention-Deficit/Hyperactivity Disorder (ADHD). In the absence of any standardized, empirically evaluated clinical strategies or interventions to prevent or decrease stimulant diversion, this project will test the effect of a brief provider-led intervention for stimulant diversion prevention among adolescents being prescribed stimulant medication in pediatric care. The investigators hypothesize that adolescents treated in pediatric practices randomized to the intervention will report decreased diversion, increased perceived risk of harm, and decreased intentions to divert compared to adolescents treated in pediatric practices randomized to treatment-as-usual. Secondary analyses will examine the effect of the intervention on additional contributing variables (e.g., patient, parent, and provider attitude and behavior change).
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Stimulant Diversion Prevention | Active Comparator | Providers will be trained in methods to prevent or decrease the likelihood of stimulant diversion by their adolescent patients (education and counseling, strategies for use by patients and parents, and treatment adjustments). |
|
| Treatment As Usual | No Intervention | Standard clinical care |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Stimulant Diversion Prevention (SDP) | Behavioral | provider training, patient/parent education and counseling, strategies for use by patients and parents, and treatment adjustments |
| Measure | Description | Time Frame |
|---|---|---|
| Diversion Activity Questionnaire (Diversion); Change from baseline across follow-up assessments | Items indicating frequency (# of times) selling, sharing, trading, or loaning stimulant medication. Diversion frequency will increase less in the SDP group between baseline and follow-up assessments. | baseline, 6 month follow-up, 12 month follow-up, 18 month follow-up |
| Perceived Risk of Harm Questionnaire; Change from baseline across follow-up assessments | Items measuring the degree to which participants believe that people risk harming themselves if they take ADHD medication without a prescription (responses range from "no risk" to "great risk"). Mean perceived harm will increase more after baseline for the SDP vs control group. | baseline, 6 month follow-up, 12 month follow-up, 18 month follow-up |
| Intentions to Divert Prescription Stimulants Questionnaire; Change from baseline across follow-up assessments | Items measuring intention to share/sell/trade stimulant medication (responses range from "I definitely will" to "I definitely will not"). Intent to divert will increase less in the SDP vs control group. | baseline, 6 month follow-up, 12 month follow-up, 18 month follow-up |
| Measure | Description | Time Frame |
|---|---|---|
| Utilization of Clinical Practice Strategies for Diversion Prevention Questionnaire | Items measuring teen's report of the frequency of provider utilization of stimulant diversion prevention techniques (responses range from "no" to "yes, more than once" in the last 6 months). Number of techniques endorsed as occurring at least once will increase. Number will increase after baseline more for the SDP than control group. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Brooke SG Molina, PhD | University of Pittsburgh | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Youth and Family Research Program, WPIC | Pittsburgh | Pennsylvania | 15213 | United States |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 33908377 | Result | Molina BSG, Joseph HM, Kipp HL, Lindstrom RA, Pedersen SL, Kolko DJ, Bauer DJ, Subramaniam GA. Adolescents Treated for Attention-Deficit/Hyperactivity Disorder in Pediatric Primary Care: Characterizing Risk for Stimulant Diversion. J Dev Behav Pediatr. 2021 Sep 1;42(7):540-552. doi: 10.1097/DBP.0000000000000923. | |
| 33446402 | Result | McGuier EA, Kolko DJ, Joseph HM, Kipp HL, Lindstrom RA, Pedersen SL, Subramaniam GA, Molina BSG. Use of Stimulant Diversion Prevention Strategies in Pediatric Primary Care and Associations With Provider Characteristics. J Adolesc Health. 2021 Apr;68(4):808-815. doi: 10.1016/j.jadohealth.2020.12.006. Epub 2021 Jan 11. |
Not provided
Not provided
The investigators will make de-identified data available to potential scientific collaborators upon request as allowed by local Institutional Review Board (IRB) regulations and after the main findings of the study have been accepted for publication. The investigators will honor requests to use data for research or teaching purposes only and that include a commitment to protect the privacy and confidentiality of the data per IRB requirements. Depending upon the size of the request, the investigators will charge, as needed, reasonable costs associated with preparation of datasets and assistance with dataset utilization.
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D001289 | Attention Deficit Disorder with Hyperactivity |
| ID | Term |
|---|---|
| D019958 | Attention Deficit and Disruptive Behavior Disorders |
| D065886 | Neurodevelopmental Disorders |
| D001523 | Mental Disorders |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| baseline, 6 month follow-up, 12 month follow-up, 18 month follow-up |
| Disclosure of Stimulant Treatment Questionnaire | Number of people and/or groups who know about the teen's ADHD medication prescription (sum total across items). Total number will decrease after baseline in the SDP vs control group. | baseline, 6 month follow-up, 12 month follow-up, 18 month follow-up |
| Diversion Activity Questionnaire (Approaches) | Number of times approached to sell or share ADHD prescription medication. Number will decrease after baseline more for the SDP than control group. | baseline, 6 month follow-up, 12 month follow-up, 18 month follow-up |
| Management of Peer Requests Questionnaire (Diversion Refusal Skills) | Increased likelihood (from "definitely not" to "definitely") of using diversion refusal skills. Score will increase after baseline more for the SDP than control group. | baseline, 6 month follow-up, 12 month follow-up, 18 month follow-up |
| Management of Peer Requests Questionnaire (Diversion Refusal Self Efficacy) | Increased ease (from "very difficult" to "very easy") in perceived use of diversion refusal skills. Score will increase after baseline more for the SDP than control group. | baseline, 6 month follow-up, 12 month follow-up, 18 month follow-up |
| Management of Peer Requests Questionnaire (Diversion Refusal Frequency) | Increased frequency (from "never" to "almost always") of using diversion refusal skills. Frequency will increase more after baseline for the SDP vs control group. | baseline, 6 month follow-up, 12 month follow-up, 18 month follow-up |
| Knowledge of Stimulant Diversion Consequences Questionnaire | Items measuring knowledge of negative consequences of diversion; mean score will increase (responses for each consequence ranges from "very unlikely" to "likely"). Mean score will increase after baseline more for the SDP than control group. | baseline, 6 month follow-up, 12 month follow-up, 18 month follow-up |
| Likelihood of Diversion Scale | Assesses likelihood (response scale ranges from "I definitely would" to "I definitely would not") of diverting medication in specific situations. Mean response across items should increase toward "I definitely would not". Likelihood of diversion mean score will change after baseline toward "I definitely would not" more for the SDP than control group. | baseline, 6 month follow-up, 12 month follow-up, 18 month follow-up |
| Approval of Diversion by Proximal Social Contacts Questionnaire | Items measuring approval of diversion by proximal social contacts; responses range from "strongly approve" to "strongly disapprove". Mean score will increase towards disapproval. Mean score will increase toward disapproval more for the SDP than control group. | baseline, 6 month follow-up, 12 month follow-up, 18 month follow-up |
| Parental Supervision and Monitoring Specific to ADHD Medication Questionnaire (Attempted) | Items measuring attempted parental monitoring of stimulant medication (e.g., During the last 6 months, how much did either of your parents try to know.......). Mean score of responses across items. Mean score will increase after baseline more for the SDP than control group. | baseline, 6 month follow-up, 12 month follow-up, 18 month follow-up |
| Parental Supervision and Monitoring Specific to ADHD Medication Questionnaire (Actual) | Items measuring actual parental knowledge of teen's stimulant medication (e.g., During the last 6 months, how much did either of your parents really know.......). Mean score of responses across items. Mean score will increase after baseline more for the SDP than control group. | baseline, 6 month follow-up, 12 month follow-up, 18 month follow-up |
| Parent-Teen Communication about Alcohol, Drugs, Diversion | Items assessing frequency of parent-teen discussion about diversion-related behavior (e.g., "Within the last 6 months, my parents talked with me about keeping my ADHD diagnosis and ADHD medication private"). Responses range from "never" to "three or more times". Number of items endorsed as occurring at least once or more often will increase after baseline more for the SDP than control group. | baseline, 6 month follow-up, 12 month follow-up, 18 month follow-up |
| 35951253 | Derived | McGuier EA, Kolko DJ, Pedersen SL, Kipp HL, Joseph HM, Lindstrom RA, Bauer DJ, Subramaniam GA, Molina BSG. Effects of Training on Use of Stimulant Diversion Prevention Strategies by Pediatric Primary Care Providers: Results from a Cluster-Randomized Trial. Prev Sci. 2022 Oct;23(7):1299-1307. doi: 10.1007/s11121-022-01411-2. Epub 2022 Aug 11. |